Page last updated: 2024-11-13

J147

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

J147: neurotrophic curcumin derivative compound that has enhanced stability and bioavailability over curcumin [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	25229652
CHEMBL ID	2387144
CHEBI ID	192601
SCHEMBL ID	12995834
SCHEMBL ID	21294999

Synonyms (37)

Synonym
n-(2,4-dimethylphenyl)-2,2,2-triluoro-n-[(e)-(3-methoxyphenyl)methylideneamino]acetamide
1807913-16-1
CHEBI:192601
j147
j-147
CHEMBL2387144
S5269
CS-3688
SCHEMBL12995834
1146963-51-0
2,2,2-trifluoroacetic acid 1-(2,4-dimethylphenyl)-2-[(3-methoxyphenyl)methylene]hydrazide
AC-35232
HY-13779
AKOS024458485
n-(2,4-dimethylphenyl)-2,2,2-trifluoro-n'-[(3-methoxyphenyl)methylidene]acetohydrazide
mfcd25976644
n-(2,4-dimethylphenyl)-2,2,2-trifluoro-n'-[(1e)-(3-methoxyphenyl)methylidene]acetohydrazide
n-(2,4-dimethylphenyl)-2,2,2-trifluoro-n'-(3-methoxybenzylidene)acetohydrazide
EX-A2235
n-(2,4-dimethylphenyl)-2,2,2-trifluoro-n'-[(e)-(3-methoxyphenyl)methylene]acetohydrazide
DB13957
AS-16718
SCHEMBL21294999
n-(2,4-dimethylphenyl)-2,2,2-trifluoro-n-[(e)-(3-methoxyphenyl)methylideneamino]acetamide
acetic acid, 2,2,2-trifluoro-, (2e)-1-(2,4-dimethylphenyl)-2-((3-methoxyphenyl)methylene)hydrazide
unii-z41h3c5bt9
acetic acid, 2,2,2-trifluoro-, 1-(2,4-dimethylphenyl)-2-((3-methoxyphenyl)methylene)hydrazide
Z41H3C5BT9 ,
n-(2,4-dimethylphenyl)-2,2,2-trifluoro-n-((e)-(3-methoxyphenyl)methylideneamino)acetamide
acetic acid, 2,2,2-trifluoro-, 1-(2,4-dimethylphenyl)-2-[(3-methoxyphenyl)methylene]hydrazide
HMS3886O17
CCG-268030
(e)-n-(2,4-dimethylphenyl)-2,2,2-trifluoro-n'-(3-methoxybenzylidene)acetohydrazide
A894156
hymzaygfknnhdn-ssdvnmtosa-n
DTXSID501045787
n-(2,4-dimethylphenyl)-2,2,2-trifluoro-n'-[(e)-(3-methoxyphenyl)methylidene]acetohydrazide

Research Excerpts

Overview

J147 is a novel drug candidate developed to treat neurological dysfunction.

Excerpt	Reference	Relevance
"J147 is a novel drug candidate developed to treat neurological dysfunction. "	( The Alzheimer's disease drug candidate J147 decreases blood plasma fatty acid levels via modulation of AMPK/ACC1 signaling in the liver. Currais, A; Fischer, W; Huang, L; Kepchia, D; Liang, Z; Maher, P, 2022)	2.43

Treatment

Excerpt	Reference	Relevance
"J147 pretreatment markedly downregulated expression of IL-6, IL-1β, and TNF-α, and the mean fluorescence intensity of ionized calcium-binding adapter protein-1 in microglia."	( J147 ameliorates sepsis-induced depressive-like behaviors in mice by attenuating neuroinflammation through regulating the TLR4/NF-κB signaling pathway. Ke, C; Liu, Y; Pan, H; Qiu, F; Zeng, C, 2023)	3.07

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

Class	Description
anilide	Any aromatic amide obtained by acylation of aniline.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (29)

Assay ID	Title	Year	Journal	Article
AID748848	Drug metabolism in mouse liver microsomes assessed as (E)-2,2,2-trifluoro-N-(4-(hydroxymethyl)-2-methylphenyl)-N'-(3-methoxybenzylidene)acetohydrazide retention time at 5 uM by LC/MS/MS analysis	2013	Bioorganic & medicinal chemistry, May-15, Volume: 21, Issue:10	Metabolism of a potent neuroprotective hydrazide.
AID748865	Drug metabolism in human liver microsomes assessed as formation of (E)-N-(2,4-dimethylphenyl)-2,2,2-trifluoro-N'-(3-hydroxybenzyli-dene)acetohydrazide at 5 uM by LC/MS/MS analysis	2013	Bioorganic & medicinal chemistry, May-15, Volume: 21, Issue:10	Metabolism of a potent neuroprotective hydrazide.
AID748853	Half life in human liver microsomes at 5 uM by LC/MS/MS analysis in presence of NADPH	2013	Bioorganic & medicinal chemistry, May-15, Volume: 21, Issue:10	Metabolism of a potent neuroprotective hydrazide.
AID748876	Drug metabolism in mouse liver microsomes assessed as metabolite M5 retention time at 5 uM by LC/MS/MS analysis	2013	Bioorganic & medicinal chemistry, May-15, Volume: 21, Issue:10	Metabolism of a potent neuroprotective hydrazide.
AID748864	Drug metabolism in human liver microsomes assessed as formation of (E)-2,2,2-trifluoro-N-(4-(hydroxymethyl)-2-methylphenyl)-N'-(3-methoxybenzylidene)acetohydrazide at 5 uM by LC/MS/MS analysis	2013	Bioorganic & medicinal chemistry, May-15, Volume: 21, Issue:10	Metabolism of a potent neuroprotective hydrazide.
AID748872	Drug metabolism in human liver microsomes assessed as formation of 3-methoxy benzaldehyde at 5 uM by LC/MS/MS analysis	2013	Bioorganic & medicinal chemistry, May-15, Volume: 21, Issue:10	Metabolism of a potent neuroprotective hydrazide.
AID748851	Drug metabolism in human liver microsomes assessed as retention time at 5 uM by LC/MS/MS analysis	2013	Bioorganic & medicinal chemistry, May-15, Volume: 21, Issue:10	Metabolism of a potent neuroprotective hydrazide.
AID748862	Half life in BALB/c mouse blood at 20 mg/kg, iv administered in corn oil by LC/MS/MS analysis	2013	Bioorganic & medicinal chemistry, May-15, Volume: 21, Issue:10	Metabolism of a potent neuroprotective hydrazide.
AID748863	Half life in BALB/c mouse brain at 20 mg/kg, iv administered in corn oil by LC/MS/MS analysis	2013	Bioorganic & medicinal chemistry, May-15, Volume: 21, Issue:10	Metabolism of a potent neuroprotective hydrazide.
AID748861	Drug metabolism in BALB/c mouse blood assessed as retention time at 20 mg/kg, iv administered in corn oil by LC/MS/MS analysis	2013	Bioorganic & medicinal chemistry, May-15, Volume: 21, Issue:10	Metabolism of a potent neuroprotective hydrazide.
AID748857	Neuroprotective activity in rat primary cortical neurons assessed as reduction in trophic factor withdrawal after 2 days by fluorescent live-dead assay	2013	Bioorganic & medicinal chemistry, May-15, Volume: 21, Issue:10	Metabolism of a potent neuroprotective hydrazide.
AID748873	Drug metabolism in human liver microsomes assessed as formation of 2,4-dimethylhydrazine at 5 uM by LC/MS/MS analysis	2013	Bioorganic & medicinal chemistry, May-15, Volume: 21, Issue:10	Metabolism of a potent neuroprotective hydrazide.
AID748849	Drug metabolism in mouse liver microsomes assessed as (E)-N'-(3,4-dihydroxybenzylidene)-N-(2,4-dimethylphenyl)-2,2,2-trifluoroacetohydrazide retention time at 5 uM by LC/MS/MS analysis	2013	Bioorganic & medicinal chemistry, May-15, Volume: 21, Issue:10	Metabolism of a potent neuroprotective hydrazide.
AID748854	Half life in mouse liver microsomes at 5 uM by LC/MS/MS analysis in presence of NADPH	2013	Bioorganic & medicinal chemistry, May-15, Volume: 21, Issue:10	Metabolism of a potent neuroprotective hydrazide.
AID748874	Drug metabolism in human liver microsomes assessed as formation of 2,4-dimethylaniline at 5 uM by LC/MS/MS analysis	2013	Bioorganic & medicinal chemistry, May-15, Volume: 21, Issue:10	Metabolism of a potent neuroprotective hydrazide.
AID748858	Drug metabolism in BALB/c mouse blood assessed as (E)-N-(2,4-dimethylphenyl)-2,2,2-trifluoro-N'-(3-hydroxybenzyli-dene)acetohydrazide retention time at 20 mg/kg, iv administered in corn oil by LC/MS/MS analysis	2013	Bioorganic & medicinal chemistry, May-15, Volume: 21, Issue:10	Metabolism of a potent neuroprotective hydrazide.
AID748852	Drug metabolism in mouse liver microsomes assessed as retention time at 5 uM by LC/MS/MS analysis	2013	Bioorganic & medicinal chemistry, May-15, Volume: 21, Issue:10	Metabolism of a potent neuroprotective hydrazide.
AID748869	Drug metabolism in mouse liver microsomes assessed as formation of 3-methoxy benzaldehyde at 5 uM by LC/MS/MS analysis	2013	Bioorganic & medicinal chemistry, May-15, Volume: 21, Issue:10	Metabolism of a potent neuroprotective hydrazide.
AID748866	Drug metabolism in mouse plasma assessed as formation of 2,4-dimethylhydrazine at 5 uM by LC/MS/MS analysis	2013	Bioorganic & medicinal chemistry, May-15, Volume: 21, Issue:10	Metabolism of a potent neuroprotective hydrazide.
AID748860	Drug metabolism in BALB/c mouse blood assessed as metabolite BM1 retention time at 20 mg/kg, iv administered in corn oil by LC/MS/MS analysis	2013	Bioorganic & medicinal chemistry, May-15, Volume: 21, Issue:10	Metabolism of a potent neuroprotective hydrazide.
AID748868	Drug metabolism in mouse plasma assessed as formation of 2,4-dimethylaniline at 5 uM by LC/MS/MS analysis	2013	Bioorganic & medicinal chemistry, May-15, Volume: 21, Issue:10	Metabolism of a potent neuroprotective hydrazide.
AID748856	Neuroprotective activity in human MC65 cells expressing C-terminal 99 amino acids from beta secretase assessed as reduction in intracellular amyloid beta toxicity after 4 days by MTT assay	2013	Bioorganic & medicinal chemistry, May-15, Volume: 21, Issue:10	Metabolism of a potent neuroprotective hydrazide.
AID748859	Drug metabolism in BALB/c mouse blood assessed as metabolite BM2 retention time at 20 mg/kg, iv administered in corn oil by LC/MS/MS analysis	2013	Bioorganic & medicinal chemistry, May-15, Volume: 21, Issue:10	Metabolism of a potent neuroprotective hydrazide.
AID748871	Drug metabolism in mouse liver microsomes assessed as formation of 2,4-dimethylhydrazine at 5 uM by LC/MS/MS analysis	2013	Bioorganic & medicinal chemistry, May-15, Volume: 21, Issue:10	Metabolism of a potent neuroprotective hydrazide.
AID748850	Drug metabolism in mouse liver microsomes assessed as (E)-N-(2,4-dimethylphenyl)-2,2,2-trifluoro-N'-(3-hydroxybenzyli-dene)acetohydrazide retention time at 5 uM by LC/MS/MS analysis	2013	Bioorganic & medicinal chemistry, May-15, Volume: 21, Issue:10	Metabolism of a potent neuroprotective hydrazide.
AID748870	Drug metabolism in mouse liver microsomes assessed as formation of 2,4-dimethylaniline at 5 uM by LC/MS/MS analysis	2013	Bioorganic & medicinal chemistry, May-15, Volume: 21, Issue:10	Metabolism of a potent neuroprotective hydrazide.
AID748875	Drug metabolism in mouse liver microsomes assessed as metabolite M4 retention time at 5 uM by LC/MS/MS analysis	2013	Bioorganic & medicinal chemistry, May-15, Volume: 21, Issue:10	Metabolism of a potent neuroprotective hydrazide.
AID748867	Drug metabolism in mouse plasma assessed as formation of 3-methoxy benzaldehyde at 5 uM by LC/MS/MS analysis	2013	Bioorganic & medicinal chemistry, May-15, Volume: 21, Issue:10	Metabolism of a potent neuroprotective hydrazide.
AID748855	Neuroprotective activity in mouse HT22 cells assessed as reduction in glutamate-induced oxidative stress incubated for 30 mins prior to glutamate-challenge measured after 24 hrs by MTT assay	2013	Bioorganic & medicinal chemistry, May-15, Volume: 21, Issue:10	Metabolism of a potent neuroprotective hydrazide.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	4 (36.36)	24.3611
2020's	7 (63.64)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 31.09

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	31.09 (24.57)
Research Supply Index	2.48 (2.92)
Research Growth Index	4.76 (4.65)
Search Engine Demand Index	56.46 (26.88)
Search Engine Supply Index	3.00 (0.95)

This Compound (31.09)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	2 (18.18%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	9 (81.82%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
hydrazine diamine : Any polyamine that contains two amino groups.	2.21	1	azane; hydrazines	EC 4.3.1.10 (serine-sulfate ammonia-lyase) inhibitor
benzofurans Benzofurans: Compounds that contain a BENZENE ring fused to a furan ring.	3.35	1
acetyl coenzyme a Acetyl Coenzyme A: Acetyl CoA participates in the biosynthesis of fatty acids and sterols, in the oxidation of fatty acids and in the metabolism of many amino acids. It also acts as a biological acetylating agent.	2.21	1	acyl-CoA	acyl donor; coenzyme; effector; fundamental metabolite
curcumin Curcumin: A yellow-orange dye obtained from tumeric, the powdered root of CURCUMA longa. It is used in the preparation of curcuma paper and the detection of boron. Curcumin appears to possess a spectrum of pharmacological properties, due primarily to its inhibitory effects on metabolic enzymes.. curcumin : A beta-diketone that is methane in which two of the hydrogens are substituted by feruloyl groups. A natural dyestuff found in the root of Curcuma longa.	5.5	9	aromatic ether; beta-diketone; diarylheptanoid; enone; polyphenol	anti-inflammatory agent; antifungal agent; antineoplastic agent; biological pigment; contraceptive drug; dye; EC 1.1.1.205 (IMP dehydrogenase) inhibitor; EC 1.1.1.21 (aldehyde reductase) inhibitor; EC 1.1.1.25 (shikimate dehydrogenase) inhibitor; EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor; EC 1.8.1.9 (thioredoxin reductase) inhibitor; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; EC 3.5.1.98 (histone deacetylase) inhibitor; flavouring agent; food colouring; geroprotector; hepatoprotective agent; immunomodulator; iron chelator; ligand; lipoxygenase inhibitor; metabolite; neuroprotective agent; nutraceutical; radical scavenger
salvianolic acid B salvianolic acid B: isolated from Salvia miltiorrhiza. salvianolic acid B : A member of the class of 1-benzofurans that is an antioxidant and free radical scavenging compound extracted from S. miltiorrhiza	3.35	1	1-benzofurans; catechols; dicarboxylic acid; enoate ester; polyphenol	anti-inflammatory agent; antidepressant; antineoplastic agent; antioxidant; apoptosis inducer; autophagy inhibitor; cardioprotective agent; hepatoprotective agent; hypoglycemic agent; neuroprotective agent; osteogenesis regulator; plant metabolite

Condition	Indicated	Relationship Strength	Studies
Acute Confusional Senile Dementia [description not available]	0	4.38	6
Alzheimer Disease A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)	1	6.38	6
Anxiety Neuroses [description not available]	0	3.52	1
Asymmetric Diabetic Proximal Motor Neuropathy [description not available]	0	3.52	1
Anxiety Feelings or emotions of dread, apprehension, and impending disaster but not disabling as with ANXIETY DISORDERS.	0	3.52	1
Anxiety Disorders Persistent and disabling ANXIETY.	0	3.52	1
Diabetic Neuropathies Peripheral, autonomic, and cranial nerve disorders that are associated with DIABETES MELLITUS. These conditions usually result from diabetic microvascular injury involving small blood vessels that supply nerves (VASA NERVORUM). Relatively common conditions which may be associated with diabetic neuropathy include third nerve palsy (see OCULOMOTOR NERVE DISEASES); MONONEUROPATHY; mononeuropathy multiplex; diabetic amyotrophy; a painful POLYNEUROPATHY; autonomic neuropathy; and thoracoabdominal neuropathy. (From Adams et al., Principles of Neurology, 6th ed, p1325)	0	3.52	1
Blood Poisoning [description not available]	0	2.6	1
Sepsis Systemic inflammatory response syndrome with a proven or suspected infectious etiology. When sepsis is associated with organ dysfunction distant from the site of infection, it is called severe sepsis. When sepsis is accompanied by HYPOTENSION despite adequate fluid infusion, it is called SEPTIC SHOCK.	0	7.6	1
Aging The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.	0	2.66	2
Genetic Diseases [description not available]	0	2.25	1
Brain Disorders [description not available]	0	2.25	1
Brain Diseases Pathologic conditions affecting the BRAIN, which is composed of the intracranial components of the CENTRAL NERVOUS SYSTEM. This includes (but is not limited to) the CEREBRAL CORTEX; intracranial white matter; BASAL GANGLIA; THALAMUS; HYPOTHALAMUS; BRAIN STEM; and CEREBELLUM.	0	2.25	1
Genetic Diseases, Inborn Diseases that are caused by genetic mutations present during embryo or fetal development, although they may be observed later in life. The mutations may be inherited from a parent's genome or they may be acquired in utero.	0	2.25	1
Chronic Kidney Diseases [description not available]	0	2.31	1
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	0	2.72	2
Renal Insufficiency, Chronic Conditions in which the KIDNEYS perform below the normal level for more than three months. Chronic kidney insufficiency is classified by five stages according to the decline in GLOMERULAR FILTRATION RATE and the degree of kidney damage (as measured by the level of PROTEINURIA). The most severe form is the end-stage renal disease (CHRONIC KIDNEY FAILURE). (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002)	0	2.31	1
Depression, Involutional Form of depression in those MIDDLE AGE with feelings of ANXIETY.	0	2.31	1
Depression Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders.	0	2.31	1
Depressive Disorder, Major Disorder in which five (or more) of the following symptoms have been present during the same 2-week period and represent a change from previous functioning; at least one of the symptoms is either (1) depressed mood or (2) loss of interest or pleasure. Symptoms include: depressed mood most of the day, nearly every daily; markedly diminished interest or pleasure in activities most of the day, nearly every day; significant weight loss when not dieting or weight gain; Insomnia or hypersomnia nearly every day; psychomotor agitation or retardation nearly every day; fatigue or loss of energy nearly every day; feelings of worthlessness or excessive or inappropriate guilt; diminished ability to think or concentrate, or indecisiveness, nearly every day; or recurrent thoughts of death, recurrent suicidal ideation without a specific plan, or a suicide attempt. (DSM-5)	0	2.31	1

chemdatabank.com